final ananova2 survival data support niraparib plus bevacizumab in recurrent ovarian cancer
Published 4 years ago • 173 plays • Length 1:42Download video MP4
Download video MP3
Similar videos
-
2:25
results of niraparib/bevacizumab combo in platinum-sensitive recurrent ovarian cancer
-
2:18
dr. mirza on efficacy of niraparib/bevacizumab combo in recurrent ovarian cancer
-
0:43
efficacy of niraparib on pfs in patients with recurrent ovarian cancer
-
1:00
rationalizing use of pembrolizumab/bevacizumab in recurrent ovarian cancer
-
0:52
dr. mirza on safety profile of niraparib/bevacizumab in recurrent ovarian cancer
-
1:19
relacorilant nab-paclitaxel in recurrent, platinum-resistant ovarian cancer
-
3:11
the avanova study: niraparib and bevacizumab for ovarian cancer
-
2:18
dr. mirza on final data of the nsgo-avanova2/engot-ov24 trial in ovarian cancer
-
6:10
ago-ovar 2.29/engot-ov34: atezolizumab vs placebo bevacizumab w/ chemo recurrent ovarian cancer
-
6:04
when to add bevacizumab for recurrent ovarian cancer
-
0:57
analyzing the survival benefits of niraparib dose modification in ovarian cancer
-
2:18
parp inhibition in recurrent ovarian cancer
-
4:54
bevacizumab in recurrent ovarian cancer
-
0:45
results for combination bevacizumab plus mirvetuximab soravtansine in ovarian cancer
-
7:32
bevacizumab for recurrent ovarian cancer
-
1:41
dr. mirza on niraparib plus bevacizumab combo in ovarian cancer
-
25:59
final overall survival results from the phase 3 solo2 trial for ovarian cancer
-
9:49
paola-1 phase 3 data: olaparib plus bevacizumab maintenance for advanced ovarian cancer
-
7:19
combination therapy with niraparib and bevacizumab for ovarian cancer